CHU Liège

• Neodjuvant/adjuvant
  NSCLC resectable Iib/IIIa
  MK3475-671
  Platinum doublet chemotherapy ± pembrolizumab
• 1-2LM
  NSCLC Squameux/non-squameux
  CANFOUR
  • Cisplatine/gemcytabine + CAN 04
  • CAN04 seul
• NSCLC
  Slots variables
  GCT1021 -01
  Humax-AXL-ADC
• NSCLC
  Slots variables
  CNIR
  PDR001 + NIR178
• adjuvant
  NSCLC RO
  GO39733
  Atezolizumab + vaccin personnalisé
• NSCLC
  Slots variables
  Pivot 02
  Nektar-IL2 + nivo Q3W

CHU Mont-Godinne

Etudes sponsorisées interventionnelles en cours:

• PEARLS: A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy.
• Intr@pid: A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Nonsmall Cell Lung Cancer.

Etudes sponsorisées non interventionnelles en cours:

• BEPACT Lung: Impact of Patient Characteristics on pneumo-oncologists NSCLC systemic treatment decision in Belgium: A cross-sectional study.

Etudes académiques non interventionnelles en cours:

• ELCWP: Cardiovascular morbidities and lung cancer treatment: a prospective registry.

Cliniques Universitaires Saint-Luc

1st line

• BO29554 study (B-FAST)
  A phase II/III multicentre study evaluating the efficacy and safety of multiple targeted therapies as treatments for patients with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring actionable somatic mutations detected in blood (B-Fast: blood-first assay screening trial)
• ADRIATIC (D933QC00001)
  Phase III, randomised, double-blind, placebo-controlled, multi-centre study assessing the efficacy and safety of durvalumab or durvalumab and tremelimumab in patients with LD-SCLC who have not progressed following definitive, platinum-based, concurrent chemoradiation therapy (CRT)
• Zenith20 (Spectrum) (SPI-POZ-202)
  A phase 2 study of poziotinib in patients with NSCLC, locally advanced or metastatic, with EGFR or HER2 exon insertion mutation

2nd/3rd line

• CACZ885V2301
  A phase III, multicenter, 2parallel cohort, randomized, double-blind study evaluating the efficacy and safety of canakinumab in combination with docetaxel vs docetaxel alone given as second or third line therapy in adult patients with NSCLC previously treated with PD(L)1 inhibitors and platin-based chemotherapy

Autres

• REVEAL D5161R00007
  REtrospective, obserVational study to describe the treatment patterns and outcomes of Epidermal Growth Factor Receptor mutant (EGFRm) locally Advanced or metastatic Non-Small-Cell Lung Cancer (NSCLC) patients in Belgium
• BEPACT
  Impact of Patient Characteristics on pneumo-oncologists NSCLC systemic treatment decision in Belgium: A cross-sectional study
• Radiomics
  Analyse Radiomique d’une cohorte de patients CPNPC traités par immunothérapie aux Cliniques Universitaire St-Luc : Un biomarqueur potentiel pour prédire et quantifier la réponse au traitement et les complications liés à l’immunothérapie
• ANAM 17-21
  A phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to evaluate the efficacy and safety of Anamorelin HCl for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced NSCLC
• EORTC: E2-Radiate 1811
  E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe

GHdC

• A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects With Extensive Stage Small Cell Lung Cancer (MERU)
• Cardiovascular morbidities and lung cancer treatment: a prospective registry
  A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab Compared With Chemotherapy in Patients With Treatment Naïve Advanced or Recurrent (Stage IIIb Not Amenable for Multimodality Treatment) or Metastatic (Stage IV) Non-Small Cell Lung Cancer Who Are Deemed Unsuitable for Platinum-Containing Therapy
• A Randomized, Phase 3 Trial With Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) Versus Placebo for Patients With Early Stage NSCLC After Resection and Completion of Standard Adjuvant Therapy (PEARLS)
• A phase III, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of canakinumab in combination with docetaxel vs placebo in combination with docetaxel in patients with non-small cell lung cancer (NSCLC) previously treated with PD(L)1 inhibitors and platin-based chemotherapy
• BEPACT Lung: Impact of Patient Characteristics on pneumo-oncologists NSCLC systemic treatment decision in Belgium: A cross-sectional study.
• A Phase 1b/2 Study To Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors
• An open-label, dose escalation phase I/II study assessing the safety and immunogenicity of PDC*lung, therapeutic cancer vaccine, as single agent or in combination with a checkpoint inhibitor, in patients with Non-Small Cell Lung Cancer (NSCLC)
• A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of anamorelin HCl for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced non-small cell lung cancer (NSCLC)
  Phase 1b Study of LY3295668 Monotherapy in Patients with Platinum-Sensitive, Extensive-Stage Small-Cell Lung Cancer
• A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)